Table S2.
Patient demographics and baseline clinical characteristics, by study
| Characteristic | Calverley et al2 (n=509) |
Szafranski et al1 (n=408) |
CLIMB 20093 (n=654) |
|---|---|---|---|
| Age, years | 64.5 (9.1) | 64.7 (8.7) | 62.4 (8.7) |
| Male, n (%) | 389 (76.4) | 325 (79.7) | 490 (74.9) |
| Lung function | |||
| Pre-bronchodilator FEV1, L | 1.19 (0.48) | 1.03 (0.37) | 1.14 (0.38) |
| Reversibility, % predicted | 5.91 (6.43) | 5.44 (5.19) | 5.23 (5.70) |
| Post-bronchodilator FEV1, % predicteda | 42.2 (3.2–79.5) | 40.6 (16.9–72.0) | 43.8 (13.7–76.9) |
| Pre-bronchodilator FEV1/VC ratio, %a | 46.1 (18.8–108.4) | 42.0 (17.5–93.4) | 47.1 (15.7–89.3) |
| Smoking history, pack-yearsa | 35.0 (10.0–240.0) | 40.0 (10.0–168.0) | 38.0 (10.0–280.0) |
| SGRQ total score | 49.70 (19.37) | 54.69 (17.44) | 62.30 (17.59) |
| Reliever use, inhalations/day | 1.83 (2.52) | 3.92 (3.18) | 4.29 (3.05) |
Notes: Data presented as arithmetic mean (standard deviation) unless otherwise stated.
a
Data are median (range).
Abbreviations: B/F, budesonide/formoterol; FEV1, forced expiratory volume in 1 s; SGRQ, St George’s Respiratory Questionnaire; VC, vital capacity.